Loading...
•
Jun 30, 2025
OraSure Q2 2025 Earnings Report
OraSure reported its second quarter 2025 financial results, with total net revenues decreasing significantly due to a decline in COVID-19 revenues, while core business revenues saw a modest decrease.
Key Takeaways
OraSure Technologies experienced a substantial 43% decrease in total net revenues for Q2 2025, primarily driven by a near-complete decline in COVID-19 related revenues. Despite this, the core business saw a more modest 5% year-over-year decrease, with Diagnostics revenues showing a 3% increase. The company reported a significant GAAP net loss and operating loss, but highlighted progress in product portfolio expansion and strategic initiatives for future growth.
Total net revenues for Q2 2025 decreased by 43% to $31.2 million, largely due to a significant decline in COVID-19 revenues.
Core business revenues, excluding COVID-19, Molecular Services, and Risk Assessment testing, decreased by 5% year-over-year to $30.8 million.
The company reported a GAAP net loss of $19.693 million and a non-GAAP net loss of $14.193 million for the quarter.
OraSure ended the quarter with $235 million in cash and cash equivalents and is focused on innovation, commercial expansion, and diversifying client relationships for future growth.
Revenue by Segment
Forward Guidance
OraSure Technologies provided guidance for Q3 2025, expecting total revenues to be between $27 million and $30 million, with minimal contribution from COVID-19 testing revenues.
Positive Outlook
- Launch of HEMAcollect™●PROTEIN product in July to meet evolving needs of proteomic researchers.
- Renewal of customer agreement with GeneDx, enabling early diagnosis of rare pediatric diseases.
- Appointment of Anne Messing as Chief Commercial Officer to drive market leadership and sustainable growth.
- Focus on advancing innovation roadmap and expanding commercial reach.
- Strong balance sheet provides flexibility to invest in organic and inorganic opportunities.
Challenges Ahead
- Expected continued decline in COVID-19 testing revenues, projected to be less than $100 thousand in Q3 2025.
- Overall revenue guidance for Q3 2025 ($27M-$30M) indicates a continued year-over-year decline.
- Uncertainty related to funding for public health programs and research.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...